CRIS News & Events

Reports Q1 revenue $0, consensus $1.86M. As of March 31 Curis's cash and cash equivalents totaled $15.0M, and the Company had approximately 40.0 million shares of common stock outstanding.

Curis believes its cash and cash equivalents as of March 31 of $15.0M, together with anticipated gross proceeds of up to an additional $20.2M from the exercise of the January 2026 PIPE Financing Series B Warrants upon the public announcement of dosing the 5th CLL patient in our TakeAim CLL study expected later this year, should enable the Company's planned operations into the second half of 2027.

Reports Q4 revenue $1.14M, consensus $3.25M. Curis believes its cash and cash equivalents as of December 31, 2025, together with initial and expected gross proceeds of the January 2026 PIPE Financing Series B Warrants, should enable the company's planned operations into the second half of 2027.

Curis files to sell 107.71M shares of common stock for holders